Anesthesia, local: Topical: Apply up to ~1 g (1 tube) per venipuncture or venous cannulation site; maximum of 5 sites may be anesthetized per course of treatment not to exceed a cumulative dose of ~7 g (7 tubes) in 24 hours.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
Anesthesia, local: Infants ≥1 month of age, Children, and Adolescents: Topical: Apply up to ~1 g (1 tube) per venipuncture or venous cannulation site not to exceed a cumulative dose of ~2 g (2 tubes) in 24 hours.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
<1%, postmarketing, and/or case reports: Application site edema (severe), application site erythema (severe), application site pruritus (severe), skin blister (application site)
Hypersensitivity to tetracaine, other ester-type anesthetic agents, or any component of the formulation; use in premature infants and full-term infants <1 month of age; application to broken skin, mucous membranes, eyes, or ears
Concerns related to adverse effects:
• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants <6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, light-headedness, fatigue).
Disease-related concerns:
• Seizures: Use with caution; may lower seizure threshold.
Other warnings/precautions:
• Immunizations: Should not be used to provide anesthesia prior to immunization.
Not available in the United States.
Solution (Pontocaine Mouth/Throat)
2% (30 mL): $19.03
Disclaimer: The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Gel, External:
Ametop: 4% (1.5 g) [delivers ~1 g]
Topical: For external use only. Apply and cover with an occlusive dressing ~30 minutes prior to venipuncture or ~45 minutes prior to venous cannulation to achieve adequate anesthesia; after area anesthetized, remove gel with a gauze swab and prepare site as normal. Avoid contact with eyes, ears, or mucous membranes. Do not apply to open or damaged skin.
Topical: For external use only. Avoid contact with eyes, ears, mucous membranes, or broken skin. Apply ~30 minutes prior to venipuncture or ~45 minutes prior to venous cannulation to achieve adequate anesthesia; after area anesthetized, remove gel with a gauze swab and prepare site as normal. Do not apply to open or damaged skin. Do not use prior to immunizations.
Note: Not approved in the United States.
Topical anesthetic: To produce anesthesia of the skin prior to venipuncture or venous cannulation, including intravenous injections of medications.
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.
Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Risk C: Monitor therapy
Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor therapy
Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor therapy
Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor therapy
Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor for signs of methemoglobinemia when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid use of these agents with prilocaine/lidocaine cream in infants less than 12 months of age. Risk C: Monitor therapy
Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor therapy
Animal reproduction studies have not been conducted.
It is not known if tetracaine is present in breast milk. Breastfeeding is not recommended by the manufacturer.
Ester local anesthetic blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction.
Metabolism: Hepatic; detoxified by plasma esterases to aminobenzoic acid
Excretion: Urine
Do you want to add Medilib to your home screen?